| Literature DB >> 25375188 |
Yeon-Ju Lee1, Jeong-Woo Lee2, Dong-Geun Lee3, Hyi-Seung Lee4, Jong Soon Kang5, Jieun Yun6.
Abstract
Eight scalarane sesterterpenoids, including four new compounds, were isolated from the marine sponge Scalarispongia sp. The structures of the new compounds were elucidated by 2D-NMR and HRMS analyses. All of the isolated compounds, with the exception of 16-O-deacetyl-12,16-epi-scalarolbutanolide, showed significant in vitro cytotoxicity (GI50 values down to 5.2 μM) against six human cancer cell lines.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25375188 PMCID: PMC4264154 DOI: 10.3390/ijms151120045
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Structures of the isolated scalarane sesterterpenoids.
1H- and 13C-NMR data (500 and 125 MHz) for compounds 5‒7.
| Position | 5 | 6 | 7 | |||
|---|---|---|---|---|---|---|
| δC, type | δH ( | δC, type | δH ( | δC, type | δH ( | |
| 1 | 39.2, CH2 | 1.64, m | 40.1, CH2 | 1.68, m | 40.2, CH2 | 1.69, m |
| 0.72, m | 0.75, ddd (12.5, 3.5, 3.5) | 0.78, ddd (12.5, 3.5, 3.5) | ||||
| 2 | 18.1, CH2 | 1.42, m | 18.8, CH2 | 1.57, m | 18.8, CH2 | 1.55, m |
| 1.22, m | 1.40, m | 1.40, m | ||||
| 3 | 41.7, CH2 | 1.20, m | 42.2, CH2 | 1.36, m | 42.2, CH2 | 1.35, m |
| 0.98, ddd (13.0,13.0, 3.5) | 0.95, ddd (12.5, 12.5, 3.5) | 1.10, ddd (13.0, 13.0, 3.5) | ||||
| 4 | 32.8, C | 33.5, C | 33.5, C | |||
| 5 | 56.1, CH | 0.76, brd (13.0) | 56.6, CH | 0.82, m | 56.7, CH | 0.78, m |
| 6 | 18.2, CH2 | 1.40, m | 18.4, CH2 | 1.54, m | 18.5, CH2 | 1.54, m |
| 1.30, m | 1.29, m | 1.40, m | ||||
| 7 | 41.7, CH2 | 1.66, ddd, (12.5, 3.0, 3.0) | 42.5, CH2 | 1.77, ddd (13.0, 4.0, 3.0) | 42.6, CH2 | 1.81, ddd (12.5, 3.0, 3.0) |
| 0.92, ddd, (12.5,12.5, 3.0) | 1.02, ddd (13.0, 13.0, 4.0) | 1.00, (12.5, 12.5, 3.0) | ||||
| 8 | 37.7, C | 38.2, C | 38.2, C | |||
| 9 | 50.6, CH | 1.32, m | 61.4, CH | 0.87, m | 61.4, CH | 0.81, m |
| 10 | 36.6, C | 37.8, C | 37.8, C | |||
| 11 | 25.2, CH2 | 1.54, m | 17.2, CH2 | 1.60, m | 17.2, CH2 | 1.59, m |
| 1.28, m | 1.38, m | 1.33, m | ||||
| 12 | 70.2, CH | 3.60, dd (3.0, 3.0) | 40.5, CH | 2.03, m | 40.7, CH | 2.03, dd (10.0, 3.0) |
| 1.33, m | 1.34, m | |||||
| 13 | 45.5, C | 41.6, C | 41.6, C | |||
| 14 | 45.1, CH | 1.19, m | 51.6, CH | 1.09, m | 51.9, CH | 1.05, m |
| 15 | 30.6, CH2 | 1.99, ddd (12.5, 8.0, 2.0) | 28.0, CH2 | 2.19, ddd (12.5, 7.0, 2.0) | 31.7, CH2 | 2.17, ddd (12.5, 7.0, 2.0) |
| 1.33, m | 1.47, m | 1.45, m | ||||
| 16 | 67.4, CH | 4.26, dd (10.0, 8.0) | 69.8, CH | 5.52, ddd (11.5, 7.0, 2.0) | 69.0, CH2 | 4.49, ddd (9.3, 7.0, 2.0) |
| 17 | 175.5, C | 167.0, C | 171.7, C | |||
| 18 | 83.3, CH | 5.06, brs | 90.0, CH | 4.33, d (2.0) | 90.1, C | 4.29, brs |
| 19 | 174.9, C | 173.0, C | 173.5, C | |||
| 20 | 110.6, CH | 5.73, brs | 112.4, CH | 5.76, dd (2.0, 2.0) | 111.9, CH2 | 5.90, brs |
| 21 | 32.9, CH3 | 0.67, s | 33.5, CH3 | 0.82, s | 33.4, CH3 | 0.83, s |
| 22 | 20.8, CH3 | 0.65, s | 21.5, CH3 | 0.78, s | 21.5, CH3 | 0.79, s |
| 23 | 16.0, CH3 | 0.68, s | 16.5, CH3 | 0.81, s | 16.5, CH3 | 0.81, s |
| 24 | 16.7, CH3 | 0.72, s | 17.7, CH3 | 0.85, s | 17.7, CH3 | 0.86, s |
| 25 | 11.6, CH3 | 0.51, s | 12.3, CH3 | 0.70, s | 12.4, CH3 | 0.69, s |
| 16-OAc | 170.0, C | |||||
| 21.1, CH3 | 2.16, s | |||||
The 1H- and 13C-NMR spectra are measured in CDCl3/CD3OD (3:1); The 1H- and 13C-NMR spectra are measured in CDCl3; Carbons correlating with the corresponding proton.
Figure 2Selected NOESY correlations for compounds 5‒8.
Figure 3Selected COSY and HMBC correlations for compounds 5‒8.
Growth inhibition of compounds 1–8 against a panel of human tumor cell lines .
| Compound | Cell Line (GI50 μM)
| |||||
|---|---|---|---|---|---|---|
| HCT-15 | NCI-H23 | ACHN | MDA-MB-231 | NUGC-3 | PC-3 | |
| 7.38 ± 0.07 | 11.0 ± 0.12 | 6.01 ± 0.02 | 6.17 ± 0.02 | 7.25 ± 0.04 | 5.45 ± 0.02 | |
| 6.52 ± 0.05 | 6.20 ± 0.09 | 5.43 ± 0.01 | 6.99 ± 0.03 | 6.13 ± 0.03 | 5.36 ± 0.03 | |
| 7.75 ± 0.08 | 5.66 ± 0.09 | 6.17 ± 0.04 | 5.41 ± 0.02 | 5.66 ± 0.03 | 5.70 ± 0.02 | |
| 8.17 ± 0.06 | 9.02 ± 0.10 | 6.99 ± 0.02 | 5.19 ± 0.03 | 8.98 ± 0.04 | 7.01 ± 0.02 | |
| >60.0 | >60.0 | >60.0 | >60.0 | >60.0 | >60.0 | |
| 9.11 ± 0.09 | 21.0 ± 0.09 | 6.69 ± 0.04 | 11.3 ± 0.08 | 21.0 ± 0.02 | 10.0 ± 0.08 | |
| 11.6 ± 0.09 | 12.2 ± 0.10 | 7.22 ± 0.07 | 5.24 ± 0.04 | 12.2 ± 0.04 | 6.53 ± 0.03 | |
| 7.85 ± 0.05 | 10.6 ± 0.07 | 6.60 ± 0.03 | 9.10 ± 0.02 | 10.2 ± 0.09 | 9.17 ± 0.04 | |
| 1.53 ± 0.02 | 1.79 ± 0.05 | 1.85 ± 0.01 | 1.76 ± 0.01 | 1.50 ± 0.02 | 1.69 ± 0.03 | |
HCT-15, colon cancer; NCI-H23, lung cancer; ACHN, renal cancer; MDA-MB-231, breast cancer; NUGC-3, stomach cancer; PC-3, prostate cancer; GI50 values are the concentrations corresponding to 50% growth inhibition. Data are an average of at least two tests.